Daniel Ebner

Group Head / PI and Member of congregation

The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.

The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens

Recent publications

HighVia—A Flexible Live-Cell High-Content Screening Pipeline to Assess Cellular Toxicity
Journal article

Howarth A. et al, (2020), SLAS DISCOVERY: Advancing the Science of Drug Discovery, 247255522092397 - 247255522092397
Transcriptomic and Functional Screens Reveal MicroRNAs That Modulate Prostate Cancer Metastasis
Journal article

Rao SR. et al, (2020), Frontiers in Oncology, 10
Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor related cytotoxicity
Journal article

Patel A. et al, (2020), International Journal of Cancer
CagA–ASPP2 complex mediates loss of cell polarity and favors H. pylori colonization of human gastric organoids
Journal article

Buti L. et al, (2020), Proceedings of the National Academy of Sciences, 117, 2645 - 2655
Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib
Journal article

Montenegro RC. et al, (2020), Oncotarget, 11

More publications